Therefore, it indicated that therapeutic strategy by upregulating AIM2 may pave a new avenue for manipulating liver cancer, and pharmacological targeting of mTOR-S6K1 pathway may be beneficial in AIM2-deficient tumors. The gene discussed is AIM2; the disease is liver cancer.